Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2023-06.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 83 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 84 Impact of statin treatment on cardiovascular events in patients with retinal vein occlusion: a nested case-control study in Korea
Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Epidemiol Health > Volume 45; 2023 > Article
Original Article Impact of statin treatment on cardiovascular events in patients with retinal vein occlusion: a nested case-control study in Korea
Joonsang Yoo1orcid , Joo Youn Shin2orcid , Jimin Jeon1orcid , Jinkwon Kim1orcid
Epidemiol Health 2023;45e2023035-0
DOI: https://doi.org/10.4178/epih.e2023035
Published online: March 15, 2023
  • 409 Views
  • 59 Download
  • 0 Crossref
  • 0 Scopus
1Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
2Department of Ophthalmology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea; 3Instutute for Innovation in Digital Healthcare, Yonsei University, Seoul, Korea
Corresponding author:  Jinkwon Kim,
Email: antithrombus@yuhs.ac
Received: 12 December 2022   • Accepted: 27 February 2023

OBJECTIVES
Retinal vein occlusion (RVO) is associated with an increased risk of future cardiovascular events. Statin therapy is a key cornerstone in prevention for patients at high cardiovascular risk. However, little is known about the role of statin therapy for patients with RVO. This study evaluated whether statin treatment in patients with RVO was associated with a lower risk of cardiovascular events.
METHODS
A population-based, nested case-control study was conducted with a cohort of newly diagnosed RVO patients without prior cardiovascular disease between 2008 and 2020 using a nationwide health claims database in Korea. From this cohort of RVO patients, we identified cases of cardiovascular events (stroke or myocardial infarction) after RVO and matched controls based on sex, age, insurance type, antiplatelet use, and underlying comorbidities using 1:2 incidence density sampling.
RESULTS
Using a cohort of 142,759 patients with newly diagnosed RVO, we selected 6,810 cases and 13,620 matched controls. A significantly lower risk of cardiovascular events (adjusted odds ratio, 0.604; 95% confidence interval, 0.557 to 0.655) was observed in RVO patients with statin treatment than in those without statin treatment. Statin treatment was associated with a reduced risk for both stroke and myocardial infarction after RVO. Longer statin treatment after RVO was associated with a lower risk for cardiovascular events.
CONCLUSIONS
Statin treatment was associated with a lower risk for future cardiovascular events in patients with newly diagnosed RVO. Further studies are warranted to clarify the potential cardiovascular preventive role of statins in patients with RVO.


Epidemiol Health : Epidemiology and Health